Topical therapy for the treatment of cervical intraepithelial neoplasia (cin) and cervical cancer using nanoparticles of taxanes

Abstract

A method of treating cervical intraepithelial neoplasia (CIN) or cervical cancer in a subject is disclosed. The method can include topically administering to an affected area of the subject a composition comprising a plurality of taxane nanoparticles, thereby treating the CIN or the cervical cancer. The taxane nanoparticles can be uncoated (neat) individual particles that are not encapsulated in, bound to, or conjugated to any substance.

1 . A method of treating cervical intraepithelial neoplasia (CIN) or cervical cancer in a subject in need of treatment, the method comprising topically administering to an affected area of the subject a composition comprising a plurality of taxane nanoparticles, thereby treating the CIN or the cervical cancer, wherein the taxane nanoparticles are uncoated (neat) individual particles that are not encapsulated in, bound to, or conjugated to any substance. 
     
     
         2 . The method of  claim 1 , wherein the taxane nanoparticles have a mean particle size (number) from 0.1 microns to 1.5 microns. 
     
     
         3 . The method of  claim 1 , wherein the composition comprises 0.1% w/w to 5% w/w of the taxane nanoparticles. 
     
     
         4 . The method of  claim 1 , wherein the taxane nanoparticles are suspended within the composition. 
     
     
         5 . The method of  claim 1 , wherein the taxane nanoparticles have a specific surface area (SSA) of at least 18 m 2 /g. 
     
     
         6 . The method of  claim 1 , wherein the taxane nanoparticles have a specific surface area (SSA) of 18 m 2 /g to 50 m 2 /g. 
     
     
         7 . The method of  claim 1 , wherein each of the taxane nanoparticles contain not less than 90% taxane. 
     
     
         8 . The method of  claim 1 , wherein each of the taxane nanoparticles contain not less than 95% taxane. 
     
     
         9 . The method of  claim 1 , wherein the composition is a hydrophobic composition. 
     
     
         10 . The method of  claim 9 , wherein the composition is an anhydrous composition. 
     
     
         11 . The method of  claim 1 , wherein the composition comprises a hydrophobic carrier. 
     
     
         12 . The method of  claim 11 , wherein the hydrophobic carrier comprises petrolatum, mineral oil, or paraffin was, or mixtures thereof. 
     
     
         13 . The method of  claim 11 , wherein the hydrophobic carrier is greater than 50% w/w of the composition. 
     
     
         14 . The method of  claim 11 , wherein the hydrophobic composition comprises one or more volatile silicone fluids. 
     
     
         15 . The method of  claim 14 , wherein the concentration of the one or more volatile silicone fluids is from 5 to 24% w/w of the composition. 
     
     
         16 . The method of  claim 14 , wherein the one or more volatile silicone fluids is cyclomethicone. 
     
     
         17 . The method of  claim 1 , wherein the plurality of taxane nanoparticles comprise cabazitaxel. 
     
     
         18 . The method of  claim 1 , wherein the subject has CIN, and wherein the CIN is treated. 
     
     
         19 . The method of  claim 1 , wherein the subject has cervical cancer, and wherein the cervical cancer is treated.